Table 2 Pathologic response of two neoadjuvant cohort.

From: Real-world comparison of neoadjuvant chemoimmunotherapy and chemotherapy in muscle-invasive bladder cancer

 

NAC (N = 71) [95% CI]

NAC.NICB (N = 29) [95% CI]

P value

Adjust P value

Pathological response

  

0.034*a

0.034c

complete response

18(25.4%) [16.7 − 36.6%]

14(48.3%) [31.4 − 65.6%]

  

partial response

16(22.5%) [14.4 − 33.5%]

8(27.6%) [14.7 − 45.7%]

  

stable disease

21(29.6%) [20.2 − 41.0%]

6(20.7%) [9.8 − 38.4%]

  

progression disease

16(22.5%) [14.4 − 33.5%]

1(3.4%) [0.6 − 17.2%]

  

pCR

  

0.034*a

0.034c

Yes

18(25.4%) [16.7 − 36.6%]

14(48.3%) [31.4 − 65.6%]

  

No

53(74.6%) [63.4 − 83.3%]

15(51.7%) [34.4 − 68.6%]

  

Pathological downstage

  

0.014*a

0.034c

Yes

34(47.9%) [36.7 − 59.3%]

22(75.9%) [57.9 − 87.8%]

  

No

37(52.1%) [40.7 − 63.3%]

7(24.1%) [12.2 − 42.1%]

  

DCR

  

0.020*b

0.034c

Yes

55(77.5%) [66.5 − 85.6%]

28(96.6%) [82.8 − 99.4%]

  

No

16(22.5%) [14.4 − 33.5%]

1(3.4%) [0.6 − 17.2%]

  
  1. pCR: Pathological complete response; DCR: disease control rate; NAC.NICB: neoadjuvant chemotherapy combined with immune checkpoint blockade; NAC: neoadjuvant chemotherapy.
  2. aChi-square test.
  3. bFisher’s exact test.
  4. cBenjamini-Hochberg(BH)adjustment.
  5. *P < 0.05 was recognized as statistically different.
Back to article page